47 results
8-K
EX-1.1
ORGS
Orgenesis Inc
11 Apr 24
Entry into a Material Definitive Agreement
4:20pm
the Germfree DMES.
“EU Market” means all countries in the European Union and the United Kingdom.
“Excluded Assets” has the meaning set forth in Section 2.2
8-K
EX-10.1
ORGS
Orgenesis Inc
7 Mar 24
Orgenesis Inc. Announces $2.3 Million Private Placement
12:11pm
and Security of the U.S. Department of Commerce), the United Nations Security Council, the European Union, or the United Kingdom (including sanctions
8-K
EX-10.1
ORGS
Orgenesis Inc
8 Nov 23
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
9:24am
, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union
8-K
EX-10.1
gqq7pgpcjfd
1 Sep 23
Entry into a Material Definitive Agreement
6:04am
8-K
EX-10.1
notvl2ncu8zguxkpj
7 Nov 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
vk9nx164jqp56 z5flj6
17 Aug 22
Entry into a Material Definitive Agreement
2:30pm
8-K
EX-10.1
dxxczzkg96bhir
5 Apr 22
Orgenesis Inc. Announces $14.8 Million Private Placement
5:10pm
8-K
EX-99.1
l2zl f33y
30 Mar 22
Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update
7:29am
424B3
aztdlruatb p73wl906
27 Nov 20
Prospectus supplement
8:36am
8-K
EX-99.1
z7r0blluqeqgoq6x2bw
16 Nov 20
Other Events
2:36pm
8-K
EX-2.1
h850x1rzx b5g752ufj
1 Oct 20
Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies
5:04pm